Company CVAbout Piramal Pharma Ltd 
Piramal Pharma Ltd
Small Cap
Pharmaceuticals & Biotechnology
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 1325.75 Cr
Number of Shares
132.57 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
28-May-2024
132.57
1325.75
2800000
10
Issued under ESOP Scheme
02-Aug-2023
132.29
1322.95
129629630
10
Right Issues
05-Sep-2022
119.33
1193.32
1193318500
10
Scheme of arrangement - Demerger
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 29 Schemes (13.11%)
FIIs
Held by 179 FIIs (30.27%)
Promoter with highest holding
The Sri Krishna Trust Through Its Trustee Mr. Ajay G Piramal And Dr. (mrs.) Swati A Piramal (26.55%)
Highest Public shareholder
Ca Alchemy Investments (17.95%)
Individual Investors Holdings
14.12%
Board of Directors
Management
Designation
Remuneration
Nandini Piramal
Chairperson
5.13 cr
PETER D DEYOUNG
Executive Director & CEO
5.16 cr
Neeraj Bharadwaj
Director
0
Jairaj Purandare
Independent Director
37.5 lacs
S Rama Dorai
Independent Director
39.0 lacs
Peter Stevenson
Independent Director
33.5 lacs
Sridhar Gorthi
Independent Director
37.5 lacs
Vibha Paul Rishi
Independent Director
22.09 lacs
Nathalie Leitch
Director
29.14 lacs
Vivek Valsaraj
Executive Director & CFO
2.94 cr
Tanya D'Costa
Company Sec. & Compli. Officer
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Cost of Materials Consumed
1596.93
0%
Cost of Materials Consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
2,044 Cr
(Quarterly Results - Sep 2025)
Net Profit:
-99 Cr
Pharmaceuticals & Biotechnology
INR 23,867 Cr (Small Cap)
NA (Loss Making)
34
0.06%
0.51
-0.55%
2.97
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
